Back to Results
Amy Larson, PhD
Post-Doctoral Research Fellow
Department + Services
Molecular Cardiology Research Institute
Clinical Focus Areas
Research Focus Areas
Hypertrophic Cardiomyopathy, RNA Biology as it relates to human disease, regulation of gene expression
WCUPA Board of Governor’s Scholarship in Science and Technology, 2004
Joe & Rita Calvo Outstanding Teaching Assistant Award, 2011
RNA Society Travel Award, 2012
Larson A+, Fair BJ+, Pleiss JA., 2016. “Interconnections Between RNA-processing Pathways Revealed by a Sequencing Based Genetic Screen for Pre-mRNA Splicing Mutants in Fission Yeast.” G3: Genes, Genomes, Genetics. 6: 1513-1523. (https://www.ncbi.nlm.nih.gov/pubmed/27172183)
Yeh CS, Chang SL, Chen JH, Wang HK, Chou YC, Larson A, Pleiss JA, Chang TH, 2017. “The Evolutionary Conserved AU-Dinucleotide at the 5’ End of U1 snRNA is Critical for the Biogenesis and Functionality of U1 snRNP.” Nucl. Acids Res. 45, 9679-9693 (https://www.ncbi.nlm.nih.gov/pubmed/28934473)
Dr. Amy Larson received her B.S. in Molecular and Cell Biology at West Chester University of PA in 2008. There she worked on regulation of different eukaryotic DNA polymerase levels during development in the lab of Dr. Erin Gestl. Amy then went on to get her PhD in Biochemistry, Molecular and Cell Biology from Cornell University. Amy performed her graduate research in the lab of Dr. Jeff Pleiss, where she developed a sequencing-based screening technique to identify mutants that were defective in pre-mRNA splicing in the fission yeast model system. Additionally, her research focused on understanding the mechanism of co-transcriptional spliceosome recruitment in multi-intronic transcripts. Amy joined the MCRI in the fall of 2017 as a postdoctoral research fellow in Dr. Michael Chin’s lab. There her research focuses on developing techniques for performing single cell RNA-Seq on primary human issue to better understand the pathogenesis of Hypertrophic Cardiomyopathy.
American Heart Assocation
Dr. Larson’s postdoctoral research is focused on understanding the pathogenesis of Hypertrophic Cardiomyopathy (HCM) at single cell resolution. She is using a combination of single cell RNA-Sequencing, whole genome sequencing, and proteomics to identify plasma biomarkers in patients with obstructive HCM.